Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Xoma Royalty has agreed to acquire HilleVax. Emeryville, Calif.-based Xoma plans to begin a tender offer for the Boston vaccine developer by Aug. 18, the biotechnology-royalty aggregator said Monday.

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

HilleVax Inc.’s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.

In Q3 2023, HilleVax announced the closing of an underwritten public offering of 9,200,000 shares of its common stock at a price of $12.50 per share for gross proceeds of $115.0 million.

HilleVax's top line data from the phase 2/3 NEST-IN1 study for the prevention of Norovirus-related gastroenteritis is expected mid-2024. Learn more on HLVX stock here.

The filing shows HilleVax had $124.5 million in cash at the end of 2021. Combined with the IPO cash, the company said it plans to spend about $125 million on clinical development of its norovirus ...